Stryker Bears Retreat Before Q3 Print

Stryker Corporation reports Q3 results on October 29 with short sellers pulling back sharply even as the stock has reclaimed ground lost earlier in the year.

Short interest has dropped roughly 18% from its late-September peak, falling to 1.5% of the free float as of October 22. The decline is steep: bears held around 7.9 million shares in late September; that position has compressed to 5.8 million. The past week alone saw an 8% increase in shares short, a partial rebuild after the larger unwind, but the overall level remains low. Borrow costs are modest at 0.52% annually, up about 12% over the week but well within the normal range for a large-cap name. Availability in the lending pool is extremely loose at 3,640% of short interest, meaning roughly 173 million shares remain available to borrow. Short sellers have little structural constraint on either side of the trade.

The bigger question heading into the print is whether management can close the gap between analyst conviction and a stock that has fallen roughly 15% year-to-date. Target prices have moved sharply lower since August. Wells Fargo cut its target from $418 to $348 in September; BTIG followed in October, trimming from $358 to $316 even while keeping a Buy rating. Barclays initiated coverage at Overweight with a $375 target in early October, a partial offset. The consensus mean now sits at roughly $363, about 18% above the October 23 close of $307. The bull case centres on Stryker's robotics franchise, MAKO 4 pipeline, and management's FY26 organic sales guidance of 8.0% to 9.5% with adjusted EPS of $14.90 to $15.10. The bear case is more immediate: a March cyber incident disrupted Peripheral Vascular supply chains, management has already guided organic growth toward the low end of its range at 8.3%, and European procedure volumes face pressure from defence spending trade-offs. Wolfe Research downgraded the stock to Peer Perform in August, a notable step down from Outperform.

Options positioning tells a mildly bullish story. The put/call ratio is running at 0.58, below its 20-day average of 0.62, a reading about 1.1 standard deviations below the recent mean. That places options traders on the more constructive side of recent history, despite the stock's price weakness. The 52-week range on the PCR runs from 0.07 to 0.96, so the current level is well within normal bounds rather than at any extreme.

One ownership note stands out. Ronda Stryker, a director and one of the company's largest individual shareholders, sold roughly $6.2 million of stock across multiple transactions on August 19, reducing her disclosed position to around 14.5 million shares. The activist register shows she filed a Schedule 13D/A in April disclosing a 4.0% stake; as-last-filed stakes around the 5% threshold can shift without further disclosure once they drop below it. Institutional flows are broadly constructive: T. Rowe Price added 1.9 million shares in the most recent quarter, and JP Morgan Asset Management added 944,000, while Greenleaf Trust trimmed 710,000.

The Q3 print will test whether the cyber-related supply disruption has been contained or is still running into the fourth quarter, and whether the underlying orthopedic and robotics franchise can deliver the volume growth that justifies the gap between the current share price and the analyst consensus.